Comparative Review Evaluates Effectiveness and Safety of Treatments for Hidradenitis Suppurativa
A recent review in JAMA Dermatology compares the efficacy and safety of various treatments for moderate-to-severe hidradenitis suppurativa, highlighting promising biologic options and the need for further research.
A comprehensive systematic review and network meta-analysis published in JAMA Dermatology examine the efficacy and safety profiles of approved and investigational medications for moderate-to-severe hidradenitis suppurativa (HS). Led by Dr. Amit Garg and colleagues from Northwell, the study analyzed data from 25 clinical trials involving 5,767 patients and 39 different treatments. The review highlights that several biologic agents, including sonelokimab, lutikizumab, adalimumab, bimekizumab, povorcitinib, and secukinumab, showed significantly higher rates of clinical response (HiSCR-50) compared to placebo. While these treatments differ in mechanisms and dosing regimens, the comparison indicates no definitive superiority of one over another, with differences in adverse event rates remaining relatively low. Serious adverse events ranged from 0% to 10% across all groups, suggesting a generally acceptable safety profile for these therapies. Overall, the findings suggest multiple effective options for managing moderate-to-severe HS but highlight the need for further research to establish clear treatment preferences based on efficacy and safety profiles.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Bird Flu Outbreak Leads to Closure of Parks in Andalusia, Spain
Bird flu outbreaks in Andalusia, Spain, have led to the closure of major parks and wildlife areas as authorities work to contain the virus and protect both wildlife and public health.
Evaluating Australia’s Medicine Approval Timeline Compared to the US
Australia's medicine approval process balances safety and efficiency, often taking longer than the US, but ensuring rigorous safety standards for public health.
New Protein Interaction Map Illuminates Breakdown of Brain Cell Communication in Alzheimer's Disease
A new comprehensive map of protein interactions reveals how communication breakdown in brain cells contributes to Alzheimer's disease, opening new paths for treatment strategies.
Updated Clinical Guidelines on Pharmacotherapy for Obesity Management
New guidelines for obesity pharmacotherapy highlight personalized treatment options, including new medications, and emphasize obesity as a chronic disease requiring long-term management strategies.